Bimekizumab
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 525 publications
Eczematous eruption during bimekizumab treatment for plaque psoriasis: a biopsy-confirmed case with elevated serum TARC and peripheral eosinophilia.
Journal: European journal of dermatology : EJD
Published: August 31, 2026
IL-17 at the eye-joint interface in psoriatic disease: mechanisms, clinical correlates, and therapeutic implications.
Journal: Expert review of clinical immunology
Published: August 10, 2026
Approved Monoclonal Antibody Therapies for Hidradenitis Suppurativa.
Journal: JAMA dermatology
Published: August 05, 2026
Speed of Response in Biologic Treatments for Moderate-to-Severe Plaque Psoriasis: Bayesian Network Meta-Analysis.
Journal: Journal of drugs in dermatology : JDD
Published: August 05, 2026
Effectiveness of bimekizumab according to previous biologic exposure in patients with plaque psoriasis: a multicenter real-world study.
Journal: The Journal of dermatological treatment
Published: July 29, 2026
The Evaluation of the Clinical Effectiveness and Safety of Biologic Therapies in Psoriasis-Real-World Evidence up to 64 Weeks of Therapy.
Journal: Medical sciences (Basel, Switzerland)
Published: July 24, 2026
Kidney function recovery in immunoglobulin A nephropathy patient following bimekizumab therapy.
Journal: BMJ case reports
Published: July 23, 2026
Neuropathic Pain Management Using Novel Biologics in Moderate-to-Severe Hidradenitis Suppurativa.
Journal: Current pain and headache reports
Published: July 16, 2026
Real-World Effectiveness and Safety of Bimekizumab for Moderate-to-Severe Hidradenitis Suppurativa: A Multicenter Retrospective Study from the Italian Landscape HS (IL-HS).
Journal: Dermatology and therapy
Published: July 14, 2026
Efficacy and drug survival after transitioning to IL-17 inhibitors in patients with psoriasis who did not respond to IL-23 inhibitors: analysis from the BIOREP registry.
Journal: The Journal of dermatological treatment
Published: July 10, 2026
Treatment Persistence and Factors Associated with Bimekizumab Discontinuation in Psoriatic Arthritis and Axial Spondyloarthritis: A Real-World Multicenter Study.
Journal: Biomedicines
Published: July 03, 2026
Effect of Bimekizumab Treatment on Health Status, Work Productivity, and Productivity Costs Through 3 Years in Axial Spondyloarthritis and Psoriatic Arthritis.
Journal: The Journal of rheumatology
Published: July 01, 2026
Last Updated: 09/26/2026